Marinus Pharmaceuticals, Inc. (MRNS) Financials
MRNS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 170.9 million | 154.1 million |
2023-09-30 | 200.8 million | 146.3 million |
2023-06-30 | 201.2 million | 143.9 million |
2023-03-31 | 226.8 million | 141.7 million |
MRNS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -27.0 million | 3.9 million |
2023-09-30 | -25.3 million | 4.0 million |
2023-06-30 | -24.4 million | 3.9 million |
2023-03-31 | -41.5 million | 3.7 million |
MRNS Net Income
No data available :(
MRNS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 150.3 million | - | 774000 |
2023-09-30 | 176.4 million | - | 1.7 million |
2023-06-30 | 175.3 million | 68.1 million | 1.8 million |
2023-03-31 | 199.2 million | 71.5 million | 2.1 million |
MRNS Shares Outstanding
MRNS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 34000 | 26.3 million | 15.4 million | - |
2023-09-30 | 85000 | 23.7 million | 14.9 million | - |
2023-06-30 | - | 21.4 million | 15.7 million | - |
2023-03-31 | - | 27.9 million | 15.2 million | - |
MRNS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 7.2 million | 1.0 million |
2023-09-30 | 7.3 million | 455000 |
2023-06-30 | 6.1 million | 386000 |
2023-03-31 | 10.4 million | 206000 |
MRNS
Price: $1.51
52 week price:
Earnings Per Share: -2.63 USD
P/E Ratio: -3.59
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 214200
Ebitda: -19.9 millionMarket Capitalization: 475.4 million